These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25492409)

  • 1. Formulation and stability of cytokine therapeutics.
    Lipiäinen T; Peltoniemi M; Sarkhel S; Yrjönen T; Vuorela H; Urtti A; Juppo A
    J Pharm Sci; 2015 Feb; 104(2):307-26. PubMed ID: 25492409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical Techniques for Structural Characterization of Proteins in Solid Pharmaceutical Forms: An Overview.
    Bolje A; Gobec S
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines and anti-cytokines as therapeutics--an update.
    Tayal V; Kalra BS
    Eur J Pharmacol; 2008 Jan; 579(1-3):1-12. PubMed ID: 18021769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical stability of nonviral plasmid-based therapeutics.
    Anchordoquy TJ; Koe GS
    J Pharm Sci; 2000 Mar; 89(3):289-96. PubMed ID: 10707010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies.
    Majumdar R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulations strategies for biopharmaceuticals--ensuring success to market.
    Atkinson EM; Klum W
    IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hurdles and leaps for protein therapeutics.
    Kozlowski S; Cherney B; Donnelly RP
    Ann N Y Acad Sci; 2009 Dec; 1182():146-60. PubMed ID: 20074283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunogenicity of therapeutic cytokines.
    Herzyk DJ
    Curr Opin Mol Ther; 2003 Apr; 5(2):167-71. PubMed ID: 12772507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
    Wright JF; Qu G; Tang C; Sommer JM
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):174-8. PubMed ID: 12669452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation, stability, and delivery of live attenuated vaccines for human use.
    Burke CJ; Hsu TA; Volkin DB
    Crit Rev Ther Drug Carrier Syst; 1999; 16(1):1-83. PubMed ID: 10099898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design to biologics development: The polysorbates point of view.
    Brovč EV; Mravljak J; Šink R; Pajk S
    Int J Pharm; 2020 May; 581():119285. PubMed ID: 32240804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation on formulation and preparation of adenovirus encoding human endostatin lyophilized powders.
    Chen S; Guo D; Guo B; Liu J; Shen Y; Xu X; Huang W; Guo S
    Int J Pharm; 2012 May; 427(2):145-52. PubMed ID: 22234038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
    Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
    Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I aerosol formulations for pulmonary delivery.
    Germershaus O; Schultz I; Lühmann T; Beck-Broichsitter M; Högger P; Meinel L
    Eur J Pharm Biopharm; 2013 Sep; 85(1):61-8. PubMed ID: 23958318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes.
    Kasper JC; Troiber C; Küchler S; Wagner E; Friess W
    Eur J Pharm Biopharm; 2013 Oct; 85(2):294-305. PubMed ID: 23747745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients.
    Santana H; González Y; Campana PT; Noda J; Amarantes O; Itri R; Beldarraín A; Páez R
    Int J Pharm; 2013 Aug; 452(1-2):52-62. PubMed ID: 23624083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of protein pharmaceuticals.
    Manning MC; Patel K; Borchardt RT
    Pharm Res; 1989 Nov; 6(11):903-18. PubMed ID: 2687836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of nanosuspensions in drug delivery.
    Wang Y; Zheng Y; Zhang L; Wang Q; Zhang D
    J Control Release; 2013 Dec; 172(3):1126-41. PubMed ID: 23954372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.